Provenge (Dendreon Corporation)


Welcome to the PulseAid listing for the Provenge drug offered from Dendreon Corporation. This Autologous Cellular Immunotherapy [EPC],Cell-mediated Immunity [PE],Cells, Cultured, Autologous [Chemical/Ingredient],Peripheral Blood Mononuclear Cells [Chemical/Ingredient] pharmaceutical is classified as a CELLULAR THERAPY. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same CELLULAR THERAPY drug type category.

LABELER NAME / MANUFACTURER: Dendreon Corporation
NON-PROPRIETARY NAME: Sipuleucel-T
SUBSTANCE NAME: SIPULEUCEL-T
TYPE: CELLULAR THERAPY
PHARMA CLASS: Autologous Cellular Immunotherapy [EPC],Cell-mediated Immunity [PE],Cells, Cultured, Autologous [Chemical/Ingredient],Peripheral Blood Mononuclear Cells [Chemical/Ingredient]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2010-04-29
END MARKETING DATE: 0000-00-00


Provenge CELLULAR THERAPY Details:

Item DescriptionProvenge from Dendreon Corporation
LABELER NAME: Dendreon Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 50000000(1-Jan)
START MARKETING DATE: 2010-04-29
END MARKETING DATE: 0000-00-00
PRODUCT ID: 30237-8900_1574a6a0-a77a-43bd-9440-314f62ecb391
PRODUCT NDC: 30237-8900
APPLICATION NUMBER: BLA125197

Other SIPULEUCEL-T Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Dendreon CorporationProvenge